Novel targeted treatment options for advanced cholangiocarcinoma

Amit Mahipal, Anuhya Kommalapati, Sri Harsha Tella, Alexander Lim, Richard Kim

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Introduction: Surgical resection remains the mainstay of potentially curative treatment in the early stages of cholangiocarcinoma, whereas for the advanced stage, systemic chemotherapeutics and experimental targeted therapies are the primary treatment options. The molecular heterogeneity of the tumor is based on location, liver dysfunction, and relative rarity of the disease and confers challenges for clinical trial enrollment. The advancements in the understanding of molecular pathogenesis of cholangiocarcinoma have led to the development of targeted therapies that are currently being evaluated in the clinical trials. Areas covered: This review summarizes the current understanding and future directions of targeted therapeutic options in the management of advanced cholangiocarcinoma. Expert opinion: Advanced cholangiocarcinoma has a dismal prognosis; improved understanding of the molecular pathogenesis and advancements in development of targeted therapy offers hope that we may improve outcomes in this rare, but highly lethal cancer. Among the newly discovered molecular alterations, targeting FGFR2 fusions, IDH1/2 mutations and HER2 receptors hold great promise for improving the future management of cholangiocarcinoma. Immunotherapy in combination with targeted agents and chemotherapy may improve outcomes. In addition, drugs targeting the MEK, EGFR, KRAS, BRAF, and ROS1 pathways and neo-angiogenesis may also provide new horizons in the management of cholangiocarcinoma.

Original languageEnglish (US)
Pages (from-to)709-720
Number of pages12
JournalExpert Opinion on Investigational Drugs
Volume27
Issue number9
DOIs
StatePublished - Sep 2 2018

Fingerprint

Cholangiocarcinoma
Therapeutics
Clinical Trials
Investigational Therapies
Mitogen-Activated Protein Kinase Kinases
Expert Testimony
Drug Delivery Systems
Immunotherapy
Liver Diseases
Neoplasms
Drug Therapy
Mutation

Keywords

  • cholangiocarcinoma
  • FGFR
  • gemcitabine
  • IDH
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Novel targeted treatment options for advanced cholangiocarcinoma. / Mahipal, Amit; Kommalapati, Anuhya; Tella, Sri Harsha; Lim, Alexander; Kim, Richard.

In: Expert Opinion on Investigational Drugs, Vol. 27, No. 9, 02.09.2018, p. 709-720.

Research output: Contribution to journalReview article

Mahipal, Amit ; Kommalapati, Anuhya ; Tella, Sri Harsha ; Lim, Alexander ; Kim, Richard. / Novel targeted treatment options for advanced cholangiocarcinoma. In: Expert Opinion on Investigational Drugs. 2018 ; Vol. 27, No. 9. pp. 709-720.
@article{f171909e4c6e46d7a970021831f52d99,
title = "Novel targeted treatment options for advanced cholangiocarcinoma",
abstract = "Introduction: Surgical resection remains the mainstay of potentially curative treatment in the early stages of cholangiocarcinoma, whereas for the advanced stage, systemic chemotherapeutics and experimental targeted therapies are the primary treatment options. The molecular heterogeneity of the tumor is based on location, liver dysfunction, and relative rarity of the disease and confers challenges for clinical trial enrollment. The advancements in the understanding of molecular pathogenesis of cholangiocarcinoma have led to the development of targeted therapies that are currently being evaluated in the clinical trials. Areas covered: This review summarizes the current understanding and future directions of targeted therapeutic options in the management of advanced cholangiocarcinoma. Expert opinion: Advanced cholangiocarcinoma has a dismal prognosis; improved understanding of the molecular pathogenesis and advancements in development of targeted therapy offers hope that we may improve outcomes in this rare, but highly lethal cancer. Among the newly discovered molecular alterations, targeting FGFR2 fusions, IDH1/2 mutations and HER2 receptors hold great promise for improving the future management of cholangiocarcinoma. Immunotherapy in combination with targeted agents and chemotherapy may improve outcomes. In addition, drugs targeting the MEK, EGFR, KRAS, BRAF, and ROS1 pathways and neo-angiogenesis may also provide new horizons in the management of cholangiocarcinoma.",
keywords = "cholangiocarcinoma, FGFR, gemcitabine, IDH, Targeted therapy",
author = "Amit Mahipal and Anuhya Kommalapati and Tella, {Sri Harsha} and Alexander Lim and Richard Kim",
year = "2018",
month = "9",
day = "2",
doi = "10.1080/13543784.2018.1512581",
language = "English (US)",
volume = "27",
pages = "709--720",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Novel targeted treatment options for advanced cholangiocarcinoma

AU - Mahipal, Amit

AU - Kommalapati, Anuhya

AU - Tella, Sri Harsha

AU - Lim, Alexander

AU - Kim, Richard

PY - 2018/9/2

Y1 - 2018/9/2

N2 - Introduction: Surgical resection remains the mainstay of potentially curative treatment in the early stages of cholangiocarcinoma, whereas for the advanced stage, systemic chemotherapeutics and experimental targeted therapies are the primary treatment options. The molecular heterogeneity of the tumor is based on location, liver dysfunction, and relative rarity of the disease and confers challenges for clinical trial enrollment. The advancements in the understanding of molecular pathogenesis of cholangiocarcinoma have led to the development of targeted therapies that are currently being evaluated in the clinical trials. Areas covered: This review summarizes the current understanding and future directions of targeted therapeutic options in the management of advanced cholangiocarcinoma. Expert opinion: Advanced cholangiocarcinoma has a dismal prognosis; improved understanding of the molecular pathogenesis and advancements in development of targeted therapy offers hope that we may improve outcomes in this rare, but highly lethal cancer. Among the newly discovered molecular alterations, targeting FGFR2 fusions, IDH1/2 mutations and HER2 receptors hold great promise for improving the future management of cholangiocarcinoma. Immunotherapy in combination with targeted agents and chemotherapy may improve outcomes. In addition, drugs targeting the MEK, EGFR, KRAS, BRAF, and ROS1 pathways and neo-angiogenesis may also provide new horizons in the management of cholangiocarcinoma.

AB - Introduction: Surgical resection remains the mainstay of potentially curative treatment in the early stages of cholangiocarcinoma, whereas for the advanced stage, systemic chemotherapeutics and experimental targeted therapies are the primary treatment options. The molecular heterogeneity of the tumor is based on location, liver dysfunction, and relative rarity of the disease and confers challenges for clinical trial enrollment. The advancements in the understanding of molecular pathogenesis of cholangiocarcinoma have led to the development of targeted therapies that are currently being evaluated in the clinical trials. Areas covered: This review summarizes the current understanding and future directions of targeted therapeutic options in the management of advanced cholangiocarcinoma. Expert opinion: Advanced cholangiocarcinoma has a dismal prognosis; improved understanding of the molecular pathogenesis and advancements in development of targeted therapy offers hope that we may improve outcomes in this rare, but highly lethal cancer. Among the newly discovered molecular alterations, targeting FGFR2 fusions, IDH1/2 mutations and HER2 receptors hold great promise for improving the future management of cholangiocarcinoma. Immunotherapy in combination with targeted agents and chemotherapy may improve outcomes. In addition, drugs targeting the MEK, EGFR, KRAS, BRAF, and ROS1 pathways and neo-angiogenesis may also provide new horizons in the management of cholangiocarcinoma.

KW - cholangiocarcinoma

KW - FGFR

KW - gemcitabine

KW - IDH

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85052907458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052907458&partnerID=8YFLogxK

U2 - 10.1080/13543784.2018.1512581

DO - 10.1080/13543784.2018.1512581

M3 - Review article

C2 - 30124336

AN - SCOPUS:85052907458

VL - 27

SP - 709

EP - 720

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 9

ER -